Physician profile
John E Rivera
NPI 1720044811
$8,907.65
in general payments reported to CMS, 2019-2025
27 companies · $1,846 in 2025
The $1,846 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $310 · 2021: $1,122 · 2022: $1,156 · 2023: $1,785 · 2024: $1,622 · 2025: $1,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,192 · Education: $61.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,192.23 |
| Education | $61.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,725.49 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,472.22 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,259.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $990.57 | 2019-2025 | |
| Lilly USA, LLC | $703.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $560.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $552.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $274.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $244.58 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $242.20 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $153.01 | 2022-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.86 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $104.13 | 2019-2022 | |
| Alkermes, INC. | $96.58 | 2020-2024 | Vivitrol |
| Abbott Laboratories | $70.55 | 2021-2023 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $68.14 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $46.22 | 2024-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.94 | 2019-2020 | |
| Circassia INC. | $41.59 | 2019 | |
| Allergan, INC. | $23.84 | 2019-2020 | |
| Mdd US Operations, LLC | $22.71 | 2019 | |
| Dexcom, INC. | $18.04 | 2025 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $17.55 | 2022 | |
| Bausch Health US, LLC | $15.02 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.38 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $12.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.